Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED’s transition into a sustainably profitable global biopharma continues to gather momentum, as evidenced in FY22 results, with growing commercial traction in China and pipeline progress with key assets. Global ambitions are now being addressed with partners. Positive fruquintinib FRESCO-2 data, completion of US FDA rolling filing, and execution of a global ex-China commercial and development deal with Takeda brings first launch of a HUTCHMED product outside of China even closer. The $400m Takeda upfront will boost the balance sheet and the prospect of further downstream economics enables HUTCHMED to focus on progressing its priority late-stage assets which, with plans to secure further strategic partnerships, should drive near-term value. Our HUTCHMED valuation is US$5.5bn (US$32.01 per ADS), £4.6bn and HK$43.2bn (534p or HK$49.94 per share).

Market information



Significant 2022 achievements catalyse a promising 2023
Update | 03 Apr 2023
Delivering commercially and strategically during FY22
Lighthouse | 02 Mar 2023
Takeda licenses fruquintinib in $1.13bn ex-China deal
Lighthouse | 24 Jan 2023

Recent News

Fruquintinib granted US Priority Review
26 May 2023
Data presentations at ASCO 2023
25 May 2023
Fruquintinib NDA accepted in China for 2L gastric cancer
18 Apr 2023
AACR 2023 presentations
12 Apr 2023